Clinical trials: NKTCL
Extranodal NK T Cell Lymphoma, Hemophagocytic Lymphohistiocytosis (HLH)
Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)
Extranodal NK/T-cell lymphoma (NKTCL) is an aggressive EBV-associated lymphoma with poor prognosis, highly prevalent in China. Early-stage NKTCL achieves favorable long-term survival, while advanced disease shows dismal outcomes…
- Trial name
- NCT07525466
- Testing
- Mitoxantrone liposome, Etoposide, Pegaspargase (PEG) Asparaginase
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Beijing Tongren Hospital
Lymphoma, Extranodal NK-T-Cell
Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL
A multicenter, prospective trial to evaluate the efficacy and safety of Selinexor, anti-PD-1 antibody plus Golidocitinib in the treatment of relapsed or refractory Natural Killer / T-cell lymphoma.
- Trial name
- NCT06573138
- Testing
- Selinexor, anti-PD-1 antibody plus Golidocitinib
- Volunteers
- 18 people
- Sponsor
- Ruijin Hospital
NKTCL, Selinexor
"Selinexor+Pegaspargase+Dexamethasone"in Ⅰ/Ⅱ NKTCL
evaluate the efficacy and safety of "Selinexor+pegaspargase+dexamethasone" in early stage NK/ T-cell lymphoma
- Trial name
- Selinexor (NCT06559553)
- Testing
- Selinexor+pegaspargase+dexamethasone
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Mingzhi Zhang
Extranodal NK/T-cell Lymphoma, Nasal Type
Clinical Study of Liposomal Mitoxantrone Hydrochloride Injection Combined With Pegaspargase in the Treatment of NKTCL
This is a multicentre, open-label, single-arm, phase I/II clinical study to evaluate the safety, efficacy and pharmacokinetics of liposomal mitoxantrone hydrochloride in combination with pegaspargase in patients with extranodal…
- Trial name
- NCT04509466
- Testing
- Part 1: Liposomal mitoxantrone hydrochloride and Pegaspargase, Part 2 (treatment-naïve patients): Liposomal mitoxantrone hydrochloride and Pegaspargase, Part 2 (relapsed or refractory patients): Liposomal mitoxantrone hydrochloride and Pegaspargase
- Where
- China
- Volunteers
- 41 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Relapsed or Refractory Peripheral T Cell Lymphoma, NKTCL
Adebrelimab Combined With SHR2554 in Relapsed/Refractory PTCL and NK/T-Cell Lymphoma
To evaluate the safety of adebrelimab combined with SHR2554 in the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL) and NK/T-cell lymphoma (NKTCL), to determine the recommended Phase 2 dose (RP2D) of the…
- Trial name
- NCT07615283
- Testing
- Adebrelimab & SHR2554
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University
NKTCL
A Phase II Study of Sintilimab, Pegaspargase and Selinexor Followed by Radiotherapy in Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma
This is a single-arm, open-label, multicenter phase II study evaluating sintilimab, pegaspargase, and selinexor followed by radiotherapy as first-line treatment for patients with newly diagnosed stage I/II extranodal natural…
- Trial name
- NCT07574528
- Testing
- Sintilimab, Pegaspargase, Selinexor
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Sun Yat-sen University
Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type
PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma
Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive form of non-Hodgkin's lymphoma and shows extremely poor survival.
- Trial name
- NCT02085655
- Testing
- pegaspargase, Gemcitabine, Oxaliplatin
- Where
- China
- Volunteers
- 264 people
- Sponsor
- Huiqiang Huang
Natural Killer/T-cell Lymphoma
Multi-modal Fusion Model and Deep Learning for Predicting Treatment Response in NKTCL
This is a multicenter prospective study to develop and validate a multimodal, deep learning-based model for predicting treatment response in patients with extranodal natural killer/T-cell lymphoma (NKTCL) receiving first-line…
- Trial name
- NCT07409168
- Volunteers
- 100 people
- Sponsor
- Sun Yat-sen University
Extranodal NK/T-cell Lymphoma
BRIDGE-NK: Immunotherapy Versus Chemotherapy Induction Followed by Autologous HSCT in Advanced NKTCL
This is a randomized, open-label, prospective, multicenter phase III superiority study in patients with newly diagnosed stage IV extranodal NK/T-cell lymphoma.
- Trial name
- BRIDGE-NK (NCT07678229)
- Testing
- GELAD regimen, MEDA regimen, LEAP regimen
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Rong Tao
Lymphoma
Selinexor, Anti-PD-1 Antibody and P-GemOx Regimen in R/R NKTCL
A multicenter, prospective trial to evaluate the efficacy and safety of Selinexor, anti-PD-1 antibody and P-GemOx in the treatment of relapsed or refractory Natural Killer / T-cell lymphoma.
- Trial name
- NCT06573151
- Testing
- Selinexor, anti-PD-1 antibody and P-GemOx
- Volunteers
- 28 people
- Sponsor
- Ruijin Hospital
Lymphoma
A Study to Assess the Clinical Efficacy and Safety of Daratumumab in Participants With Relapsed or Refractory Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type
The purpose of this study is to assess the clinical efficacy and safety of daratumumab in relapsed or refractory natural killer/T-cell lymphomas (NKTCL).
- Trial name
- NCT02927925
- Testing
- Daratumumab
- Where
- 17 sites in China, Hong Kong and 3 more
- Volunteers
- 32 people
- Sponsor
- Janssen Research & Development, LLC
Natural Killer/T-cell Lymphoma, Relapsed or Refractory Lymphoma Including ENKL
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL
This open-label, multicenter Ib/II phase clinical trial investigates the safety, tolerability, and preliminary efficacy of tislezumab (anti-PD-1 monoclonal antibody), golidocitinib (JAK1/STAT3 signaling pathway inhibitor), and…
- Trial name
- NCT06966154
- Testing
- tislezumab, golidocitinib, Selinexor
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Fudan University
Natural Killer/T-cell Lymphoma
PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL
Natural killer/T-cell lymphoma (nasal type) is a mature T/NK-cell lymphoma closely associated with Epstein-Barr virus (EBV), with a high prevalence among populations in Asia and South America.
- Trial name
- NCT07380984
- Testing
- PD-1 antibody, radiotherapy, Chidamide
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Ruijin Hospital
Extranodal Natural Killer/T Cell Lymphoma
Sintilimab and Linperlisib Combination Treatment in Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma
This is an open-label, phase Ib study evaluating the combination treatment of sintilimab and linperlisib in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (NKTCL).
- Trial name
- NCT06793956
- Testing
- Sintilimab and Linperlisib Combination Treatment
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Sun Yat-sen University
Extranodal NK/T-cell Lymphoma, NK/T-cell Lymphoma
Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma
This is a multicenter, open-label, phase Ib/II study evaluating tislelizumab in combination with zeprumetostat (SHR2554) in patients with relapsed or refractory NK/T-cell lymphoma after at least one prior asparaginase-based…
- Conditions
- Extranodal NK/T-cell Lymphoma, NK/T-cell Lymphoma, Relapsed or Refractory NK/T-Cell Lymphoma
- Trial name
- EpiRev-NKT (NCT07502768)
- Testing
- Tislelizumab, Zeprumetostat
- Where
- China
- Volunteers
- 107 people
- Sponsor
- Rong Tao
Lymphoma, Extranodal NK-T-Cell, EBV
Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma
To investigate the efficacy of autologous EBV-specific T-cells for the treatment of patients with aggressive EBV positive extranodal NK/T-cell lymphoma
- Trial name
- CITADEL (NCT01948180)
- Testing
- baltaleucel-T
- Where
- 11 sites in United States, France and 2 more
- Volunteers
- 15 people
- Sponsor
- Cell Medica Ltd